Immunic, Inc.
IMUXNASDAQHealthcare● Active
$12.06
$-0.71(-5.56%)
Market Cap$119014580
P/E Ratio—
52W High$15.77
52W Low$5.06
Immunic, Inc. (IMUX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
IMUX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$1.08
Est. -$0.71 · -52.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
IMUX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$1.18 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.71 | -$1.08 | -52.1% | — | — | — |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.90 | -$1.20 | -33.3% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.18 | -$0.13 | +27.8% | — | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.18 | -$0.20 | -11.1% | — | — | — |
| — Q2 FY2025 | May 15, 2025 | -$0.25 | -$0.25 | +0.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.22 | -$0.25 | -13.6% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.22 | -$0.24 | -9.1% | — | $0.00B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$1.18
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$1.08
EPS Est.
-$0.71
EPS Surpr.
-52.1%
Revenue
—
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$1.20
EPS Est.
-$0.90
EPS Surpr.
-33.3%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.18
EPS Surpr.
+27.8%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.20
EPS Est.
-$0.18
EPS Surpr.
-11.1%
Revenue
—
Q2 FY2025
May 15, 2025
EPS Actual
-$0.25
EPS Est.
-$0.25
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.25
EPS Est.
-$0.22
EPS Surpr.
-13.6%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.24
EPS Est.
-$0.22
EPS Surpr.
-9.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.53 | $1.53 | $1.53 | 5 |
| Q3 FY2028 | $1.50 | $1.50 | $1.50 | 5 |
| Q2 FY2028 | $1.53 | $1.53 | $1.53 | 6 |
| Q1 FY2028 | $0.83 | $0.83 | $0.83 | 3 |
| Q4 FY2027 | $-0.81 | $-0.81 | $-0.81 | 2 |
| Q3 FY2027 | $-0.77 | $-0.77 | $-0.77 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -52.1% | $11.90 | $12.95 | +8.82% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -33.3% | $9.10 | $9.48 | +4.18% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +27.8% | $7.60 | $7.13 | -6.18% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -11.1% | $9.79 | $9.02 | -7.87% |
| ▲ Q2 FY2025 | May 15, 2025 | +0.0% | $9.77 | $9.96 | +1.94% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -13.6% | $12.00 | $10.90 | -9.17% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -9.1% | $11.80 | $11.80 | +0.00% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +8.7% | $11.70 | $13.40 | +14.53% |
Q2 FY2026+8.82%
Report Date
May 13, 2026
EPS Beat/Miss
-52.1%
Price Before
$11.90
Price After
$12.95
Q1 FY2026+4.18%
Report Date
Feb 26, 2026
EPS Beat/Miss
-33.3%
Price Before
$9.10
Price After
$9.48
Q4 FY2025-6.18%
Report Date
Nov 13, 2025
EPS Beat/Miss
+27.8%
Price Before
$7.60
Price After
$7.13
Q3 FY2025-7.87%
Report Date
Aug 7, 2025
EPS Beat/Miss
-11.1%
Price Before
$9.79
Price After
$9.02
Q2 FY2025+1.94%
Report Date
May 15, 2025
EPS Beat/Miss
+0.0%
Price Before
$9.77
Price After
$9.96
Q1 FY2025-9.17%
Report Date
Mar 31, 2025
EPS Beat/Miss
-13.6%
Price Before
$12.00
Price After
$10.90
Q4 FY2024+0.00%
Report Date
Nov 7, 2024
EPS Beat/Miss
-9.1%
Price Before
$11.80
Price After
$11.80
Q3 FY2024+14.53%
Report Date
Aug 8, 2024
EPS Beat/Miss
+8.7%
Price Before
$11.70
Price After
$13.40
Avg Beat Reaction+3.43%
Avg Miss Reaction-0.81%
Beat Rate3 / 8 quarters
Largest Move+14.53% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: IMUX ends December
Immunic, Inc. (IMUX) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-1.08 — missing the analyst consensus of $-0.71 by -52.1%. The next IMUX earnings date is expected around September 1, 2026.
Each quarter, investors track IMUX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. IMUX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
IMUX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
IMUX earnings · 5 questionsImmunic, Inc.'s next earnings report is expected around September 1, 2026. IMUX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; IMUX historically reports after market close (AMC).
IMUX earnings datewhen is IMUX earningsIMUX next earnings datewhen does IMUX report earningsIMUX earnings calendar
▸ Source: FMP · Immunic, Inc. SEC filings · US GAAP · Immunic, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026